# Rituximab and Belimumab Combination Therapy in PR3 Vasculitis

> **NCT03967925** · PHASE2 · UNKNOWN · sponsor: **Rachel Jones** · enrollment: 31 (actual)

## Conditions studied

- ANCA Associated Vasculitis
- Granulomatosis With Polyangiitis

## Interventions

- **DRUG:** Belimumab
- **DRUG:** Rituximab
- **DRUG:** Prednisolone

## Key facts

- **NCT ID:** NCT03967925
- **Lead sponsor:** Rachel Jones
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-02-01
- **Primary completion:** 2023-04
- **Final completion:** 2023-11
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2022-03-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03967925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03967925, "Rituximab and Belimumab Combination Therapy in PR3 Vasculitis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03967925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*